A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT07928258

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07928258. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in Human, Phase 1 Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

Study identification

NCT ID: NCT07928258
Recruitment status: Not yet recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 370 participants

Conditions and interventions

Conditions

Interventions

LY4336619 Drug
Sofetabart Mipitecan (Sofe-M) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2026 (Estimated)
Primary completion: Mar 2032 (Estimated)
Completion: Mar 2032 (Estimated)
Last update posted: Nov 10, 2026

2026 – 2032

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 10

Facility	City	State	ZIP	Site status
HonorHealth	Scottsdale	Arizona	85258	—
City of Hope	Duarte	California	91010	—
University of California, San Diego (UCSD) - Moores Cancer Center	La Jolla	California	92037	—
The University of Chicago Medical Center (UCMC)	Chicago	Illinois	60637	—
Harvard Medical School - Massachusetts General Hospital (MGH) - Cancer Center	Boston	Massachusetts	02114-2621	—
South Texas Accelerated Research Therapeutics (START) - New York - Long Island	Lake Success	New York	11042	—
New York University (NYU) Clinical Cancer Center	New York	New York	10016	—
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Rese -T	Columbus	Ohio	43210	—
MD Anderson Cancer Center	Houston	Texas	77030	—
START Mountain Region	West Valley City	Utah	84119	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07928258, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 10, 2026 · Synced Nov 13, 2026